Analysis identifies over 100 pipeline drug candidates for type 2 diabetes
A new industry report by DelveInsight examines the current global clinical landscape for type 2 diabetes, highlighting over 100 therapies currently under development.
DelveInsight has released a comprehensive analysis of the pharmaceutical pipeline for type 2 diabetes. The report details the status of more than 100 clinical programs, ranging from early-stage discovery and preclinical research to late-stage phase III trials.
The development landscape features a mix of global pharmaceutical companies, such as Eli Lilly, Novo Nordisk, and Pfizer, alongside specialized clinical-stage firms. These companies are exploring various therapeutic approaches, including oral medications and subcutaneous injections, to improve patient outcomes and simplify treatment regimens.
Key advancements noted in the report include the progress of oral insulin delivery systems, such as those being developed by Oramed Pharmaceuticals, and the continued evaluation of GLP-1 receptor agonists. These candidates represent the industry's attempt to address the metabolic complexities of diabetes and reduce the long-term risk of cardiovascular and kidney damage.
The research provides a structural overview of the market, categorizing therapies by their mechanism of action, route of administration, and molecule type. It serves as a benchmark for assessing which therapeutic candidates may impact the diabetes market in the near future.